Knight Therapeutics Inc.
TSX:GUD.TODrug Manufacturers - Specialty & Generic
+$0.07 today
- Market cap
- $1.14B
- Beta
- 0.07
- P/E (TTM)
- 164.6
- EPS (TTM)
- $0.06
Volume 0.04M
Average 0.10M
GUD.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Knight Therapeutics Inc.TSX: GUD.TO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of CA$9.41M rose 96.6% year over year, ahead of the +45.4% change in trailing-twelve-month research & development. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.
Context
- Research & development amounted to 6.4% of revenue in FY2025, up 0.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +96.6% holds above the trailing-twelve-month pace of +45.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 28.98M CAD
- Year-over-year change
- +24.4%
- 4-year CAGR
- +22.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.98M | +24.4% |
| FY2024 | 2024-12-31 | 23.3M | +32.8% |
| FY2023 | 2023-12-31 | 17.55M | +18.9% |
| FY2022 | 2022-12-31 | 14.76M | +16.3% |
| FY2021 | 2021-12-31 | 12.69M | — |
Research & Development vs competitors
How GUD.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +45.4% is the 2nd highest of 6, against a peer median of +9.4%.
- Research & development amounts to 6.6% of revenue for GUD.TO, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$33.61M CAD | +45.4% | +25.2% | 6.6% | |
| LTM Mar 2026 | CA$32.77M CAD | +92.4% | +40.5% | 27.5% | |
| LTM Mar 2026 | CA$13.33M CAD | -25.6% | -7.0% | 20.0% | |
| LTM Mar 2026 | CA$10.02M CAD | +9.4% | — | 3.7% | |
| LTM Mar 2026 | CA$4.85M CAD | +31.9% | -15.1% | 1.5% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | -39.8% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding GUD.TO) | — | +9.4% | -11.0% | 1.5% | |
Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 243.48M | 293.56M | 328.2M | 371.3M | 450.09M |
| Cost of Revenue | 128.07M | 155.5M | 175.55M | 196.9M | 299.35M |
| Gross Profit | 115.41M | 138.06M | 152.65M | 174.41M | 150.74M |
| Gross Margin | 47.4% | 47.0% | 46.5% | 47.0% | 33.5% |
| Research & Development | 12.69M | 14.76M | 17.55M | 23.3M | 28.98M |
| Selling, General & Admin | 74.38M | 88.62M | 83.69M | 99.35M | 123.96M |
| Operating Expenses | 128.24M | 155.12M | 155.54M | 167.01M | 152.94M |
| Depreciation & Amortization | 47.92M | 62.62M | 50.4M | 53.11M | 56.57M |
| EBITDA | 42.59M | 25.26M | 40.9M | 64.38M | 54.37M |
| EBITDA Margin | 17.5% | 8.6% | 12.5% | 17.3% | 12.1% |
| Operating Income | (5.32M) | (2.4M) | (2.89M) | 7.4M | (2.2M) |
| Operating Margin | -2.2% | -0.8% | -0.9% | 2.0% | -0.5% |
| Interest Income | 7.38M | 10.63M | 12.58M | 10.41M | 6.21M |
| Interest Expense | 3.62M | 6.6M | 12.49M | 9.22M | 10.42M |
| Other Income / Expenses | 19.52M | (2.92M) | (19.1M) | (5.35M) | (4.5M) |
| Income Before Tax | 6.69M | (43.96M) | (21.99M) | 2.05M | (6.7M) |
| Pre-Tax Margin | 2.7% | -15.0% | -6.7% | 0.6% | -1.5% |
| Income Tax Expense | (8.99M) | (14.07M) | (5.15M) | (2.28M) | (1.33M) |
| Net Income | 15.68M | (29.89M) | (16.84M) | 4.33M | (5.37M) |
| Net Margin | 6.4% | -10.2% | -5.1% | 1.2% | -1.2% |
| EPS (Basic) | 0.13 | (0.26) | (0.16) | 0.04 | (0.05) |
| EPS (Diluted) | 0.13 | (0.26) | (0.16) | 0.04 | (0.05) |
| Weighted Avg Shares | 124.48M | 114.89M | 107.47M | 101.04M | 99.57M |
| Weighted Avg Shares (Diluted) | 124.52M | 114.89M | 107.47M | 101.44M | 99.57M |
Knight Therapeutics Inc.
TSX:GUD.TO
Intrinsic Alpha fair value
Locked
Current Price
$11.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.